Flu Drug Approved in Japan Claims to Stop Virus in 24 Hours

One dose of the medication, called Xofluza, cripples influenza by interfering with an enzyme critical for viral replication.

kerry grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, SANOFI PASTEURHealth authorities in Japan on Friday (February 23) approved a new flu medication, called baloxavir marboxil (Xofluza), that aims to stop the virus within one day, according to The Wall Street Journal.

The drug works by blocking the flu virus’s ability to use the host cell for replication. That’s a different mechanism from oseltamivir (Tamiflu), an anti-influenza medication available in the U.S. that works by blocking the virus’s neuraminidase enzyme, preventing its escape from the host cell.

“The data that we’ve seen looks very promising,” Martin Howell Friede, head of the World Health Organization’s advisory on vaccines, told the Journal earlier in the month. “This could be a breakthrough in the way that we treat influenza.”

Data from the drugmaker, Shionogi, show that while Xofluza works days faster than Tamiflu in stopping the flu virus, symptoms wrap up in about the same timeframe for either medication. Roche, which makes Tamiflu, has acquired the license to sell Xofluza ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • kerry grens

    Kerry Grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo